Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.58 |
| ▸ | NOS3 | P29474 | 1/20 | 0.57 |
| ▸ | NOS2 | P35228 | 1/20 | 0.57 |
| ▸ | FEN1 | P39748 | 7/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | MPL | P40238 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319794 | 0.80 | NPC1 (0.50) | DYRK1AFEN1ALOX5APTOP2ASCN9A | |
| SCHEMBL5990646 | 0.79 | KIF11 (0.57) | TOP2ASCN9AKIF11 | |
| SCHEMBL320181 | 0.78 | DYRK1A (0.54) | DYRK1ANOS3NOS2FEN1ALOX5AP | |
| SCHEMBL11818566 | 0.77 | NOS3 (0.63) | DYRK1ANOS3NOS2MKNK1MKNK2 | |
| SCHEMBL13261852 | 0.76 | DYRK1A (0.42) | DYRK1ANOS3NOS2MKNK1MKNK2 | |
| SCHEMBL320908 | 0.76 | S1PR1 (0.46) | FEN1ALOX5APTOP2ASCN9ASCN5A | |
| SCHEMBL319626 | 0.76 | DYRK1A (0.55) | DYRK1ASCN9AMKNK1MKNK2ROCK1 | |
| SCHEMBL59927 | 0.74 | NOS3 (1.00) | DYRK1ANOS3NOS2BACE1 | |
| SCHEMBL29432593 | 0.74 | NOS3 (1.00) | DYRK1ANOS3NOS2BACE1 | |
| Hydrochloric Acid SCHEMBL31372470 | 0.73 | NOS3 (0.96) | DYRK1ANOS3NOS2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| EP-2590972-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| EP-2590972-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| EP-2590972-A2 | CHEMICAL COMPOUNDS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109667-A1 | Chemical Compounds | SCN1A, SCN7A, SCN1B | DYRK1A 2225/4885NOS3 2153/4885NOS2 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.